Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B
Journal of Cardiac Failure · 2026
DOI: 10.1016/j.cardfail.2026.02.049 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2026. Verfasst von Farooq H Sheikh und 13 weiteren Autor:innen. Beteiligte Einrichtung: MedStar Heart and Vascular Institute/Georgetown University School of Medicine, Washington, DC. Electronic address: farooq.h.sheikh@medstar.net. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Renal Insufficiency, Chronic, RNA, Small Interfering. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alnylam Pharmaceuticals Inc.
Abstract (Originalsprache)
BACKGROUND: In HELIOS-B (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy), vutrisiran reduced the risk of all-cause mortality and cardiovascular events associated with ATTR-CM. We assessed the effects of vutrisiran on renal function and on outcomes by renal function. METHODS: Patients were randomized to double-blind treatment with vutrisiran 25 mg or placebo every 3 months for ≤36 months. We evaluated the proportion of patients with a ≥40% decline in the estimated glomerular filtration rate (eGFR) from baseline and the primary composite end point (all-cause mortality or recurrent cardiovascular events) in subgroups based on baseline eGFR levels, and development of chronic kidney disease (CKD) stage ≥4 (eGFR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MedStar Heart and Vascular Institute/Georgetown University School of Medicine, Washington, DC. Electronic address: farooq.h.sheikh@medstar.net.
- Assistance Publique des Hôpitaux de Paris, Hôpital Ambroise Paré, Service de Néphrologie, Boulogne-Billancourt, France.
- National Amyloidosis Centre, University College London, London, UK.
- Assistance Publique des Hôpitaux de Paris, Nephrology Department Henri Mondor Hospital University, University Paris Est Créteil, and National Institute of Health and Medical Research U955, Créteil, France.
- Hospital Universitario Puerta de Hierro, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
- Duke University School of Medicine, Durham, North Carolina.
Förderung
- Alnylam Pharmaceuticals Inc
Zitieren
APA
Sheikh, F. H., Dang, J., Fontana, M., Audard, V., Garcia-Pavia, P., Khouri, M. G., Jobbeé-Duval, A., Brailovsky, Y., Gillmore, J., Zheng, H., Eraly, S., Moffitt, C., Yilmaz, A., & HELIOS-B TRIAL INVESTIGATORS (2026). Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2026.02.049
Vancouver
Sheikh FH, Dang J, Fontana M, Audard V, Garcia-Pavia P, Khouri MG, et al. Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B. Journal of Cardiac Failure. 2026. doi:10.1016/j.cardfail.2026.02.049
BibTeX
@article{Sheikh2026,
author = {Sheikh, Farooq H and Dang, Julien and Fontana, Marianna and Audard, Vincent and Garcia-Pavia, Pablo and Khouri, Michel G and Jobbeé-Duval, Antoine and Brailovsky, Yevgeniy and Gillmore, Julian and Zheng, Hua and Eraly, Satish and Moffitt, Colleen and Yilmaz, Ali and HELIOS-B TRIAL INVESTIGATORS, HELIOS-B TRIAL INVESTIGATORS},
title = {Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B},
journal = {Journal of Cardiac Failure},
year = {2026},
doi = {10.1016/j.cardfail.2026.02.049}
}
EUVIMED